135964-75-9

Basic information

• Product Name: Benzoic acid, 4-(hydroxymethyl)-2-nitro-, methyl ester
• CAS NO: 135964-75-9
• Molecular Formula: C9H9NO5
• Molecular Weight: 211.174
• Mol File: 135964-75-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(hydroxymethyl)-2-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(hydroxymethyl)-2-nitro-, methyl ester(135964-75-9)
• EPA Substance Registry System: Benzoic acid, 4-(hydroxymethyl)-2-nitro-, methyl ester(135964-75-9)

Safety Data

• Hazardous Substances Data: 135964-75-9(Hazardous Substances Data)

Upstream product

• 55737-62-7 methyl 4-(chlorocarbonyl)-2-nitrobenzoate 
• 5292-45-5 dimethyl 2-nitroterephthalate 
• 35092-89-8 4-(methoxycarbonyl)-3-nitrobenzoic acid 

Downstream Products

• 1034975-11-5 2-nitro-4-piperidin-1-ylmethyl-benzoic acid methyl ester 
• 1207090-46-7 methyl 4-{[(methylsulfonyl)oxy]methyl}-2-nitrobenzoate 
• 135964-76-0 methyl 4-(chloromethyl)-2-nitrobenzoate 
• 578019-96-2 methyl 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-nitrobenzoate 
• 913078-85-0 2-amino-4-{[2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}-5-(trifluoromethyl)phenoxy]methyl}benzoic acid 
• 913078-84-9 methyl 2-amino-4-{[2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}-5-(trifluoromethyl)phenoxy]methyl}benzoate 

Relevant articles and documents

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Further optimization of sulfonamide analogs as EP1 receptor antagonists: Synthesis and evaluation of bioisosteres for the carboxylic acid group

4-{[2-[(2-Furylsulfonyl)(isobutyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoic acid analogs 2a and b and a series of the acid analogs, in which the carboxylic acid residue of 2b was replaced with various kinds of carboxylic acid bioisosteres, were synthesized and evaluated as EP1 receptor antagonists. Compound 2b and its monocyclic acid analogs, in which the carboxylic acid residue of 2b was replaced with monocyclic acid bioisosteres, were found to show potent EP1 receptor antagonist activity. Optimization of the linker Y between the phenyl moiety and the carboxylic acid residue of 2b was also carried out (Table 5). Compounds 2b and 16 and 17 possessing conformationally restricted linker Y were found to show the most optimized potency among the tested compounds. Cytochrome P450 inhibition of optimized compounds was also investigated. Details of the structure-activity relationship study are presented.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.